Rallybio Corp
Close on Oct 19, 2026
- Market cap
- $94.80M
- P/E (TTM)
- 2.1
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $200.00K | $0.36 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $200.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $200.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | $38.00K | $-0.25 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $300.00K | $-0.26 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $300.00K | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.47 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | Before market open | – | $-0.50 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 9, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 6, 2023 | Before market open | – | – | – |
Press releases
Announcements Rallybio filed with the SEC
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer This presentation and the accompanying slides and oral
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Avenzo Therapeutics and Rallybio Corporation
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Transaction and Company Overview March
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Candid Therapeutics and Rallybio Corporation
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Other events · EX-99.1 to Form 8-K
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Regulation FD disclosure · EX-99.1 to Form 8-K
RLYB116 • • • • ▪ ▪ ▪ ▪ Source: Rallybio IPC2001 data
Regulation FD disclosure · EX-99.2 to Form 8-K
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Rallybio Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
Results of operations · Regulation FD disclosure · EX-99#2 to Form 8-K
Rallybio Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
Regulation FD disclosure · EX-99.1 to Form 8-K
Rallybio Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Rallybio Reports First Quarter 2022 Financial Results
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
MARCH 2022 TAKING A DEVASTATING DISEASE – AND DEVASTATING IT. We’re going there. Corporate Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K